Top Conversations from 2023 Tandem Meetings
Catch up with some of CGTLive’s top conversations from the annual ASTCT and CIBMTR meeting.
Bringing Solid Tumors into the Cell Therapy Space
Alison Betof Warner, MD, PhD, assistant attending physician, Memorial Sloan Kettering Cancer Center, discussed the solid tumor session she chaired at the 2023 Tandem Meetings.
Amer Beitinjaneh, MD, MSc, MPH, FACP, on Treating EBV+ PTLD With Tab-cel
The associate professor of medicine at Sylvester Comprehensive Cancer Center discussed updated data from the phase 3 ALLELE study.
Marco Davila, MD, PhD, on Investigating Mechanisms of CAR T Resistance in B-cell Malignancies
The vice chair for cellular therapies at Roswell Park Comprehensive Cancer Center discussed new research from the center presented at the 2023 Tandem Meetings.
Chiraag Kapadia on Investigating Clonal Hematopoiesis After CAR T-cell Therapy
The MD, PhD candidate at Baylor College of Medicine discussed findings from a new study presented at the 2023 Tandem Meetings.
Matthew Frank, MD, PhD, on Investigating CD22 CAR for LBCL After CD19 Relapse
The assistant professor of BMT and cellular therapy discussed updated safety and efficacy data on CD22 CAR T-cell therapy.
Everett Meyer, MD, PhD, on Reducing GvHD in Leukemia Treatment
The assistant professor of medicine and pediatrics at Stanford University discussed updated data from 2 studies of Orca-T cell therapy.
Brian Van Tine, MD, PhD, on Bringing Cell Therapy Into Synovial Sarcoma Treatment
The professor medicine and pediatrics at Washington University in St. Louis overviewed data from the SPEARHEAD-1 trial of afami-cel.
Bhagirathbhai Dholaria, MBBS, on Administering Axi-Cel in the Outpatient Setting for LBCL
The assistant professor of medicine at Vanderbilt University Medical Center discussed results from a retrospective analysis presented at the 2023 Tandem Meetings.
ctDNA Assay Panel Predicts CAR-T Response in Multiple Myeloma
It was found that ctDNA levels at 28 days post-treatment were significantly higher for patients who ultimately progressed by 90 days post-treatment.
Surbhi Sidana, MD, on Assessing Ide-cel in Patients With R/R Multiple Myeloma and Renal Impairment
The assistant professor of medicine, bone marrow transplantation and cellular therapy, Stanford, discussed favorable data from a real-world experience study.
Christa Krupski, DO, MPH, on Reinfusion of Tisagenlecleucel in B-ALL
The hematologist/oncologist at Cincinnati Children’s discussed unfavorable outcomes with tisa-cel reinfusion in patients with B-cell acute lymphocytic leukemia.
Ide-cel Demonstrates PFR and ORR Benefit Over Standard of Care in Triple-Class-Exposed R/R Multiple Myeloma
Median PFS was 13.3 months in the ide-cel arm, compared to 4.4 months for the SOC arm.
Madeleine Powys, MBBS, on Delivering Libmeldy to Children With Metachromatic Leukodystrophy
The locum consultant of pediatric BMT and leukemia at Royal Manchester Children’s Hospital discussed the limited distribution model of arsa-cel in Europe.
CD22-CAR Shows Promise in LBCL After CD19 Relapse
Patients with large B-cell lymphoma had an ORR of 68% and a CR rate of 53%.
Gene Therapy Yields 100% 1-Year Survival in LAD-1
No adverse events related to RP-L201 have been reported to date.
Bispecific CAR-T Shows Promising Efficacy in Mantle Cell Lymphoma
Among the 14 patients with relapsed/refractory mantle cell lymphoma who were treated with LV20.19 CAR in the trial, the overall response at 28 days post-treatment was 100%.
Hematopoietic Cell-based Gene Therapy Shows Durable Response in Fanconi Anemia
Long-term hematologic stability has been observed in at least 6 out of 10 patients with at least 12 months of follow-up.
Nirav Shah, MD, on New Data on Zamto-cel in DLBCL, Mantle Cell Lymphoma
The associate professor of medicine at Medical College of Wisconsin discussed trials assessing the dual, CD19/CD20-targeting CAR T therapy.
Tabelecleucel Demonstrates Efficacy, Safety in Phase 3 Trial for EBV-positive Post-transplant Lymphoproliferative Disease
Among 43 patients who had EBV+ PTLD following allogeneic hematopoietic cell transplant or solid organ transplant, the overall response rate was 51.2%.
Pyruvate Kinase Deficiency Gene-Edited Cell Therapy Sustains Hemoglobin Normalization
Neither patient treated with RP-L301 required RBC transfusions at any point post-engraftment.
1-Year Data on Omidubicel Shows Sustained Benefits, Reduced Infection Rates
There was a continued trend toward improvement of overall survival with omidubicel at 73% compared with UCBT at 60%.
ZUMA-7 Axi-Cel Superiority Calls for Treatment Paradigm Shift in R/R LBLC
The analysis of data from ZUMA-7 demonstrated significant efficacy for axi-cel over second-line standard treatment.
Axi-Cel, Tisa-Cel Have Comparable Efficacy in Follicular Lymphoma, Analysis Shows
Tisa-cel was associated with a more favorable safety profile in the analysis.
Durable Response Seen With Axi-Cel in Non-Hodgkin Lymphoma
In this population, median progression-free survival was nearly 40 months.
NKT Cell Therapy KUR-502 Effective for B-Cell Malignancies
KUR-502 elicited promising response rates for patients with relapsed or refractory B-cell malignancies in a phase 1 study.
T-allo10 Cell Infusion After Haploidentical HSCT Is Safe, Well-Tolerated, Prelim Data Show
The treatment seeks to improve immune reconstitution and graft-versus-leukemia immune response without increasing the risk of GvHD in children and young adults with hematologic malignancies.
Off the Shelf NK Cell Therapy Feasible in R/R Acute Myeloid Leukemia, Myelodysplastic Syndrome
Preliminary findings from the phase 1 clinical trial demonstrate good cell persistence and expansion in vivo.
Real-World Experience With Beti-cel for Patients With TDT Is Consistent With Trials
The real-world data support the recently published results from a phase 3 study, which showed most patients achieved transfusion independence.
LentiGlobin for Sickle Cell Disease: 24-Month Follow-Up Yields Sustained QOL Outcomes
The greatest improvements were seen in the Pain, Fatigue, and Physical Functioning domains.
